PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma.
Homicsko K, Zygoura P, Norkin M, Tissot S, Shakarishvili N, Popat S, Curioni-Fontecedro A, O'Brien M, Pope A, Shah R, Fisher P, Spicer J, Roy A, Gilligan D, Rusakiewicz S, Fortis E, Marti N, Kammler R, Finn SP, Coukos G, Dafni U, Peters S, Stahel RA.
Homicsko K, et al. Among authors: fisher p.
J Immunother Cancer. 2023 Oct;11(10):e007585. doi: 10.1136/jitc-2023-007585.
J Immunother Cancer. 2023.
PMID: 37880184
Free PMC article.